MedImmune Completes Enrollment in Phase 3 Study Comparing Numax to Synagis
15th Dec 2005, 21:39 GMT
- Company Also Completes Enrollment in Numax Study in Congenital Heart Disease Patients -
MedImmune Completes Enrollment in Phase 3 Study Comparing Numax to Synagis related news:
- MedImmune Completes Enrollment in Phase 3 Study Comparing Numax(TM) to Synagis(R)- Company Also Completes Enrollment in Numax Study in Congenital Heart Disease Patients - — mysan.de
- Unither Pharmaceuticals Completes Enrollment in 1st of 2 Phase III Trials of OvaRex in Advanced Ovarian Cancer — Obstetrics/ Gynecology News from StratCenter.com
- Saegis Pharmaceuticals Completes Phase IIa Clinical Study of SGS518 — Bio-Technology News from StratCenter.com
- MedImmune receives FluMist study boost — Pharmaceutical Business Review Online
- MedImmune präsentiert positive Resultate zu CAIV-T — Nachrichten Ticker - www.finanzen.net
- Viral Genetics, Inc.: Viral Genetics Updates on South African Clinical Development Initiatives — Market Wire - Pharmaceuticals and Biotech
- MedImmune Nasal Flu Vaccine Beats Flu Shots in Trial — RedOrbit News - Health
- MedImmune says new FluMist better than a shot — Latest news from Baltimore Business Journal
- MedImmune deal could pay partner $100M — bizjournals.com Health Care:Pharmaceuticals headlines
- Mochida Pharmaceutical Completes Early Phase II Clinical Trial of Epadel Indicated for Alzheimer's Disease — Japan Corporate News
Latest news from Pharmaceuticals News from StratCenter.com:
- Spectrum Pharmaceuticals to Receive $5 mln Milestone Payment From PAR Pharmaceutical for Sumatriptan Injection
- Medco to Present at the Credit Suisse Annual Healthcare Conference
- Bob Dole Medicare Podcast Helps Seniors through 2007 Drug Coverage Enrollment Process
- Unique Sugar Improves Energy, Pain and Quality of Life in Fibromyalgia and Chronic Fatigue Patients!
- Care Clinic Purchases Pinnacle Easy Care
- Pegasystems Enhances 2 Business Critical BPM Frameworks for the Healthcare Industry
- Isis Cholesterol Drug Shown Effective
- Taro Receives Marketing Authorization in UK for Etopan XL Tablets 600 mg, Etodolac
- Nymox Reports Q3 2006 Financial Results
- RemoteMDx Raises $6 mln in Private Placement